Build Imaging Risk-Prediction Biomarker Software

1. 1

   Understand risk prediction versus diagnosis

   Most radiology AI detects a finding on the current scan; this category instead outputs a probability of future disease (for example, a breast cancer risk score from a mammogram, like Clairity's Allix5). Because it forecasts rather than diagnoses, it is a conceptually and regulatorily distinct product. Design around producing a calibrated, actionable risk score, not a finding.

2. 2

   Build and validate the biomarker models

   The core is extracting quantitative imaging biomarkers and training models that predict future risk, validated against long-term outcomes, which is a harder evidence problem than detecting a present finding. Calibration and generalization across populations are critical, because a miscalibrated risk score misguides care. Longitudinal outcome data is your key asset and constraint.

3. 3

   Choose the regulatory pathway deliberately

   Predictive risk tools can follow a different path than diagnostic devices; some clear via de novo (as Allix5 did) rather than a standard 510(k) predicate, and requirements hinge on claims. Map the pathway to your exact intended use early, because the regulatory strategy shapes the whole product. Do not assume the diagnostic-AI playbook applies.

4. 4

   Fit into screening and risk-stratification workflows

   A risk score is only useful if it changes decisions: who gets screened more often, who gets supplemental imaging, who enters a high-risk program. Integrate into screening and risk-stratification workflows and make the score actionable for clinicians. Value comes from the decision it informs, not the number alone.

5. 5

   Sell on prevention and downstream value

   Buyers (health systems, screening programs, and potentially payers) value earlier risk identification and better-targeted screening. Build the health-economic and outcomes case, because a predictive tool's value is downstream and must be demonstrated. This links to the value-assessment service that is its own card.

6. 6

   Distinguish from detection and oncology tracking

   This is neither a findings-detection tool (QAS triage) nor a longitudinal tumor-tracking suite; it is forward-looking risk from imaging biomarkers. Be precise about the claim, because the regulatory path, evidence, and buyer differ. Clarity on what you predict, and for whom, defines the business.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.